The U.S. Federal Drug Administration is right now weighing in on the heated debate over drug coated stents versus metal ones. Stents are implanted in patients to stop heart attacks. They're looking into evidence that drug-coated stents-- may lead to dangerous blood clots. It's a huge concern that's effecting millions of heart patients. It's also effecting the $5 billion dollar drug-coated stent industry. Sue Herera talks with two industry analysts on "Power Lunch."
Dhulsini De Zoysa is Managing Director at SG Cowen Securities and Thom Gunderson is Medical Technology Analyst from Piper Jaffray.